PT966301E - Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i - Google Patents

Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i

Info

Publication number
PT966301E
PT966301E PT97936334T PT97936334T PT966301E PT 966301 E PT966301 E PT 966301E PT 97936334 T PT97936334 T PT 97936334T PT 97936334 T PT97936334 T PT 97936334T PT 966301 E PT966301 E PT 966301E
Authority
PT
Portugal
Prior art keywords
class
identification
mhc
heavy chain
genes involved
Prior art date
Application number
PT97936334T
Other languages
English (en)
Inventor
Klaus Frueh
Young Yang
Kwangseog Ahn
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of PT966301E publication Critical patent/PT966301E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT97936334T 1996-07-31 1997-07-31 Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i PT966301E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2284796P 1996-07-31 1996-07-31
US4621397P 1997-05-12 1997-05-12

Publications (1)

Publication Number Publication Date
PT966301E true PT966301E (pt) 2005-06-30

Family

ID=26696435

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97936334T PT966301E (pt) 1996-07-31 1997-07-31 Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i

Country Status (8)

Country Link
US (1) US6033671A (pt)
EP (1) EP0966301B1 (pt)
AT (1) ATE288764T1 (pt)
AU (1) AU730351B2 (pt)
DE (1) DE69732498T2 (pt)
ES (1) ES2237800T3 (pt)
PT (1) PT966301E (pt)
WO (1) WO1998004285A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7526298A (en) * 1997-04-18 1998-11-13 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP2140879A1 (en) * 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
WO2011119920A2 (en) * 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2772265T (pt) 2010-05-14 2018-04-20 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes e seus usos
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
BR112015021945A8 (pt) 2013-03-05 2019-12-03 Univ Oregon Health & Science vetores de citomegalovírus humanos ou animais e seus usos
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016011293A1 (en) 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
CN114317611A (zh) 2015-02-10 2022-04-12 俄勒冈健康与科学大学 可用于产生非典型cd8+t细胞应答的方法和组合物
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
US10532099B2 (en) 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877004A (en) * 1991-07-05 1999-03-02 American Cyanamid Compound Human cytomegalovirus containing a β-glucuronidase marker gene
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
AU7526298A (en) * 1997-04-18 1998-11-13 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)

Also Published As

Publication number Publication date
EP0966301B1 (en) 2005-02-09
US6033671A (en) 2000-03-07
ES2237800T3 (es) 2005-08-01
DE69732498D1 (de) 2005-03-17
AU3903297A (en) 1998-02-20
EP0966301A1 (en) 1999-12-29
ATE288764T1 (de) 2005-02-15
EP0966301A4 (en) 2001-09-05
WO1998004285A1 (en) 1998-02-05
AU730351B2 (en) 2001-03-08
DE69732498T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
PT966301E (pt) Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i
Floettmann et al. Cytostatic effect of Epstein–Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines
Zhang et al. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins.
Andersson et al. Reduced allorecognition of adenovirus-2 infected cells.
Lenschow et al. Expression and functional significance of an additional ligand for CTLA-4.
US6361770B1 (en) Method of enhancing expression of MHC class I molecules bearing endogenous peptides
Koszinowski et al. The role of CD4 and CD8 T cells in viral infections
Dill et al. Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice.
GR3017915T3 (en) Antigens composed of "major histocompatibility complex" class I antigens and specific carrier molecules, their production and use.
Sekaly et al. Antigen presentation to HLA class II-restricted measles virus-specific T-cell clones can occur in the absence of the invariant chain.
Davis et al. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
CA2165458A1 (fr) Proteines intracellulaires de liaison (pil) et leurs utilisations
Toomey et al. MHC class I expression protects target cells from lysis by Ly49‐deficient fetal NK cells
Abed et al. T cell-independent and T cell-dependent B cell activation increases IFN-gamma R expression and renders B cells sensitive to IFN-gamma-mediated inhibition.
US20030118568A1 (en) Viral stealth technology to prevent T cell-mediated rejection of xenografts
Busch et al. MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies—a tool for decreased immunogenicity of allogeneic tissue and cell transplants
Wesch et al. Differential expression of natural killer receptors on Vδ1 γδ T cells in HIV-1-infected individuals
Bagriacik et al. CD43 potentiates CD3‐induced proliferation of murine intestinal intraepithelial lymphocytes
KR980009278A (ko) 사람 파필로마 바이러스 18형 e6 단백질에 대한 인체의 면역성 조절기능을 갖는 펩타이드
Kuzushima et al. Inhibitory effect of herpes simplex virus infection to target cells on recognition of minor histocompatibility antigens by cytotoxic T lymphocytes.
KR0166425B1 (ko) 한탄 바이러스에 대한 인체 면역조절기능을 가진 펩타이드
Moller et al. IgA and rheumatoid factor in ankylosing spondylitis
Spencer et al. Know thyself: variations in self peptidomes and their immunologic consequences
LoRBER et al. Control of cloned alloreactive T lymphocyte proliferative responses: a possible role for cell-surface-bound alloantigen
Jacobson et al. Virus-specific HLA class II-restricted cytotoxic T cells